Portola Pharmaceuticals   Print Page    Close Window

Corporate Profile

Portola Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic diseases. The Company’s two FDA-approved medicines are Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], the first and only antidote for... Read More

Stock Quote
NASDAQ PTLA (Common Stock)
$20.08 - 0.33
Stock chart for: PTLA.O.  Currently trading at $20.08 with a 52 week high of $56.70 and a 52 week low of $18.18.
11/13/18 4:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.
Upcoming EventsMore >>
Portola Pharmaceuticals, Inc. at the Citi’s Global Healthcare Conference
Thursday, December 6, 2018

Archived Events
Portola Pharmaceuticals, Inc. at Credit Suisse’s 27th Annual Healthcare Conference
Tuesday, November 13, 2018 2:50 p.m. MT
LocationScottsdale, AZ

Q3 2018 Portola Pharmaceuticals, Inc. Financial Results Conference Call
Wednesday, November 7, 2018 4:30 p.m. ET